Identification of risk factors associated with postoperative acute kidney injury after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy: a retrospective study

Abstract

Background: Acute kidney injury (AKI) is a postoperative complication associated with significant morbidity and mortality. The incidence and risks factors for AKI after cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) have not been fully studied. The purpose of this study was to identify perioperative risk factors predictive of AKI after CRS-HIPEC.

Methods: This retrospective study collected demographic, tumour-related, intraoperative and postoperative data from 475 patients who underwent CRS-HIPECs. AKI was defined using the acute kidney injury network criteria and calculated on postoperative days 1, 2, 3, 7 and day of hospital discharge. We conducted univariate and multivariate analyses to assess the association between variables of interest and AKI. A p value of <0.05 was considered statistically significant.

Results: The incidence of AKI was 21.3%. The multivariate analysis identified six predictor factors independently associated with the development of AKI (OR: [95%CI]); age: 1.16 (1.05–1.29, p < 0.005), BMI (overweight: 1.97 [1.00–3.88], p = 0.05) and obesity: 2.88 (1.47–5.63), p < 0.002)), preoperative pregabalin: 3.04 (1.71–5.39, p < 0.037), platinum-based infusion: 3.04 (1.71–5.39, p < 0.001) and EBL: 1.77 (1.27–2.47, p < 0.001). Splenectomy had a protective effect (OR: 0.44 (0.25–0.76, p < 0.003).

Conclusions: Our study demonstrates that the incidence of AKI is high. While other studies have reported that AKI is associated with platinum-based infusion, age and obesity, we report for the first time a negative association between pregabalin use and AKI. More studies are needed to confirm our results.

Keywords:

• Kidney injury
• hyperthermia
• surgery
• chemotherapy

Disclosure statement

The authors have not conflict of interest to disclose.

Additional information

Funding

This work was partially supported by a Cancer Center Support Grant (CCSG) from the University of Texas MD Anderson Cancer Center, Houston, TX, USA.